COBRE: OK MED RES FOUND: CORE IV: MRI IMAGING IN VIVO

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 MRI/MRS核心设备的总体目标是提供非侵入性的活体监测能力，可用于评估大多数疾病发病过程中发生的形态、生理、病理生理和代谢过程。MRI/MRS核心设备的一个主要焦点是在实验性转基因小鼠或大鼠模型中研究心血管疾病的各个方面的体内发病机制。在5个拟议项目中，至少有3个项目将利用核磁共振/磁共振波谱核心设施作为主要组成部分，并从磁共振成像和/或磁共振波谱研究中受益匪浅。其余两个拟议项目可能会在未来拟议的活体项目中使用MRI和/或MRS技术。因此，最重要的是建立核磁共振成像/MRS核心，并与每一名研究人员就拟议的项目直接互动，如下文进一步详细讨论的那样。该核心将能够在体内具体地提供(1)形态评估，其将在任何心血管相关组织或血管中提供高达100#m分辨率的“微观”组织学信息，(2)磁共振血管成像形式的血管特异性图像，(3)血管流速，(4)使用新近开发的血管特异性造影剂增强心血管发病机制的造影剂图像，(5)使用新开发的用造影剂标记的单抗增强参与心血管疾病发病的特定内皮受体的造影剂图像，以及(6)与组织损伤或生物能量学的变化有关的代谢过程。核磁共振/MRS核心设施将在新提议的俄克拉荷马州医学研究基金会核磁共振/MRS设施内建立，该设施位于贝尔大楼，由雷尔·A·汤纳博士指导。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The general objective of the MRI/MRS Core facility is to provide non-invasive in vivo monitoring capabilities that can be used to assess morphological, physiological, pathophysiological and metabolic processes that occur during progressive stages of the pathogenesis of most diseases. A major focus of the MRI/MRS Core facility is to study the in vivo pathogenesis of various aspects of cardiovascular diseases in experimental transgenic mice or rat models. At least three of the 5 proposed projects will utilize the MRI/MRS Core facility as a major component and significantly benefit from magnetic resonance imaging (MRI) and/or magnetic resonance spectroscopy (MRS) studies. The remaining 2 proposed projects will possibly use MRI and/or MRS techniques in future proposed in vivo projects. As a result it is of the utmost importance that the MRI/MRS Core is established and that it directly interacts with each of the researchers respective to the proposed projects as discussed in further detail below. The core will be able to specifically provide in vivo (1) morphological assessment that will provide "microscopic" histology information in any cardiovascular-associated tissue or vascular vessel up to 100 #m resolution, (2) vascular specific images in the form of magnetic resonance angiography, (3) vascular flow velocity, (4) contrast agent image enhancement of cardiovascular pathogenesis with the use of recently-developed vascular-specific contrast agents, (5) contrast agent image enhancement of specific endothelial receptors that are involved in the pathogenesis of a cardiovascular disease using newlydeveloped monoclonal antibodies tagged with a contrast agent, and (6) metabolic processes relating to changes in either tissue injury or bioenergetics. The MRI/MRS Core facility will be established in the newly-proposed Oklahoma Medical Research Foundation MRI/MRS Facility located in the Bell Building, under the direction of Dr. Rheal A. Towner.